Description

Overview

DSIP (Delta Sleep-Inducing Peptide), also known as emideltide, is a synthetic nonapeptide investigated primarily for sleep regulation and sleep-related neurological research. It is not an FDA-approved treatment for insomnia or other sleep disorders.

Potential Benefits Under Research

DSIP has been investigated for:

• Sleep initiation and sleep quality
• Sleep architecture and circadian regulation
• Stress and neuroendocrine responses
• Neurological and sleep-related research

Early human research reported changes in sleep following intravenous administration, but the available evidence is limited and inconsistent, so these findings do not establish DSIP as an effective insomnia treatment.

How It May Work

The exact mechanism of DSIP remains uncertain. Research has examined possible effects on sleep-regulating and neuroendocrine pathways, but a clinically established mechanism for treating insomnia has not been demonstrated.

Strength

DSIP 10 mg

The 10 mg designation represents the stated quantity of peptide in the product. It is not an FDA-approved or clinically validated human dose. Human studies identified by FDA used different research formulations and routes, so those results should not be used to establish a 10 mg regimen.

Safety Considerations

Human safety information remains limited. FDA states that compounded emideltide may present concerns related to immunogenicity, peptide impurities, and inadequate characterization, and that insufficient safety information is available for proposed routes of administration.

Additional concerns include:

• Unknown long-term safety
• Uncertain effects with repeated use
• Product purity and sterility
• Limited evidence for commonly marketed sleep claims

Regulatory Status

DSIP/emideltide is not an FDA-approved drug. In 2026, FDA reviewed emideltide free base and acetate for potential inclusion on the 503A bulk-drug list and identified insufficient evidence and safety concerns.

Conclusion

DSIP 10 mg is an investigational peptide marketed for sleep-related research. Although historical human studies have explored its effects on sleep, evidence for clinical effectiveness remains insufficient, and 10 mg should be regarded as a product quantity rather than an established therapeutic dose.